PL211582B1 - Chiral N-Cbz blocked dimethylcyclopropane amino acid and process for the preparation thereof - Google Patents
Chiral N-Cbz blocked dimethylcyclopropane amino acid and process for the preparation thereofInfo
- Publication number
- PL211582B1 PL211582B1 PL389321A PL38932109A PL211582B1 PL 211582 B1 PL211582 B1 PL 211582B1 PL 389321 A PL389321 A PL 389321A PL 38932109 A PL38932109 A PL 38932109A PL 211582 B1 PL211582 B1 PL 211582B1
- Authority
- PL
- Poland
- Prior art keywords
- dimethylcyclopropane
- cbz
- amino acid
- chiral
- blocked
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- -1 dimethylcyclopropane amino acid Chemical class 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 7
- DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- PBIJFSCPEFQXBB-UHFFFAOYSA-N 1,1-dimethylcyclopropane Chemical compound CC1(C)CC1 PBIJFSCPEFQXBB-UHFFFAOYSA-N 0.000 claims description 5
- CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 claims description 5
- KKUHCAMYDDZIAF-QWHCGFSZSA-N OC(=O)C[C@@H]1C(C)(C)[C@@H]1CNC(=O)OCC1=CC=CC=C1 Chemical compound OC(=O)C[C@@H]1C(C)(C)[C@@H]1CNC(=O)OCC1=CC=CC=C1 KKUHCAMYDDZIAF-QWHCGFSZSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229950005228 bromoform Drugs 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 3
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 238000004809 thin layer chromatography Methods 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000012074 organic phase Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims 1
- 238000005911 haloform reaction Methods 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Przedmiotem wynalazku jest nowy chiralny N-Cbz blokowany aminokwas dimetylocyklopropanu, należący do grupy usztywnionych aminokwasów oraz sposób wytwarzania chiralnego N-Cbz z blokowanego aminokwasu dimetylocyklopropanu, przydatnego w przemyśle farmaceutycznym, jako usztywniony aminokwas.The present invention relates to a new chiral N-Cbz blocked amino acid dimethylcyclopropane belonging to the group of stiffened amino acids, and a method for the preparation of chiral N-Cbz from blocked dimethylcyclopropane amino acid useful in the pharmaceutical industry as a stiffened amino acid.
Chiralny N-Cbz blokowany aminokwas dimetylocyklopropanu, będący kwasem (+)-[(1S,3R)-3-({[(benzyloksy)karbonylo]amino}metylo)-2,2-dimetylo-cyklopropylo]octowym, o wzorze 1, ma określoną, jednoznaczną budowę przestrzenną i nie został dotychczas opisany w literaturze.Chiral N-Cbz dimethylcyclopropane blocked amino acid, which is (+) - [(1S, 3R) -3 - ({[(benzyloxy) carbonyl] amino} methyl) -2,2-dimethylcyclopropyl] acetic acid, Formula 1 has a specific, unambiguous spatial structure and has not been described in the literature so far.
Struktura związku jest usztywniona przez obecność ugrupowania gem-dimetylocyklopropanowego. Nowy usztywniony aminokwas dimetylocyklopropanu należy do grupy analogów neurotransmiterów i może być wykorzystany w przemyśle farmaceutycznym jako potencjalny terapeutyk w leczeniu chorób neurodegeneracyjnych, takich jak: choroba Parkinsona, Alzheimera, schizofrenia czy epilepsja. Nowy związek może być także stosowany jako monomer do konstruowania łańcuchów peptydowych o określonej konformacji.The structure of the compound is stiffened by the presence of a gem-dimethylcyclopropane moiety. The new stiffened amino acid dimethylcyclopropane belongs to the group of neurotransmitter analogues and can be used in the pharmaceutical industry as a potential therapeutic in the treatment of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, schizophrenia or epilepsy. The new compound can also be used as a monomer to construct peptide chains of a specific conformation.
Sposób wytwarzania nowego kwasu (+)-[(1S,3R)-3-({[(benzyloksy)karbonylo]amino}metylo)-2,2-dimetylocyklopropylo]octowego o wzorze 1 polega na tym, że ketokarbaminian dimetylocyklopropanu w postaci (-)-[(1S,3R)-2,2-dimetylo-3-(2-oksapropylo)cyklopropylo]metylokarbaminianu benzylu, poddaje się reakcji haloformowej z podbrominem sodu. Przy czym reakcję prowadzi się początkowo w temperaturze 0-5°C, a po wkropleniu całości substratu w temperaturze pokojowej. Reakcję prowadzi się aż do momentu całkowitego przereagowania ketokarbaminian dimetylocyklopropanu, co stwierdza się za pomocą chromatografii TLC. Powstały bromoform oddziela się poprzez ekstrakcję z eterem dietylowym, a nadmiar podbrominu sodu usuwa się za pomocą pirosiarczynu sodu rozpuszczonego w wodzie destylowanej. Po zakwaszeniu mieszaniny, korzystnie 10% wodnym roztworem H2SO4, przeprowadza się ekstrakcję z eterem dietylowym. Po osuszeniu fazy organicznej bezwodnym siarczanem magnezu, oddestylowuje się rozpuszczalnik, a surowy produkt oczyszcza się metodą chromatografii kolumnowej na silikażelu z użyciem mieszaniny eluującej heksan : aceton, użytej w proporcji 5:1.The method of producing the new (+) - [(1S, 3R) -3 - ({[(benzyloxy) carbonyl] amino} methyl) -2,2-dimethylcyclopropyl] acetic acid of formula 1 consists in the fact that dimethylcyclopropane ketocarbamate in the form ( Benzyl -) - [(1S, 3R) -2,2-dimethyl-3- (2-oxapropyl) cyclopropyl] methylcarbamate, reacts haloform with sodium hypobromite. The reaction is carried out initially at a temperature of 0-5 ° C, and after all the starting material has been added dropwise at room temperature. The reaction is carried out until the dimethylcyclopropane ketocarbamate has completely reacted as judged by TLC chromatography. The resulting bromoform is separated by extraction with diethyl ether and the excess sodium hypobromite is removed with sodium metabisulfite dissolved in distilled water. After acidifying the mixture with preferably 10% aqueous H 2 SO 4 solution, extraction is carried out with diethyl ether. After drying the organic phase with anhydrous magnesium sulfate, the solvent was distilled off and the crude product was purified by column chromatography on silica gel with a 5: 1 hexane: acetone eluting mixture.
Przedmiot wynalazku jest przedstawiony wzorami, z których wzór 2 jest uzupełniony o numerację atomów węgla, opisanych w interpretacji widma NMR oraz na schemacie reakcji i w przykładzie realizacji sposobu.The subject of the invention is represented by the formulas, the formula 2 of which is supplemented by the numbering of the carbon atoms described in the interpretation of the NMR spectrum and in the reaction scheme and in the embodiment of the method.
Do okrągłodennej, trójszyjnej kolby o pojemności 150 ml dodaje się 2.20 g NaOH oraz 11,00 ml wody destylowanej. Kolbę zaopatrza się w mieszadło magnetyczne i termometr, a w celu schłodzenia mieszaniny do temperatury 0°C kolbę umieszcza się w łaźni wodno-lodowej. Podczas intensywnego mieszania wkrapla się 2,64 g (16,50 mmola, 0,85 cm3) bromu z taką szybkością, aby temperatura mieszaniny nie wzrosła powyżej 5°C. Po wychłodzeniu mieszaniny do 0°C, wkrapla się 1,60 g (5,50 mmola) ketokarbaminianu dimetylocyklopropanu o czystości 90%. Dalszą część reakcji prowadzi się w temperaturze pokojowej, a po dwóch godzinach od momentu dodania substratu, można zauważyć zmianę barwy mieszaniny z pomarańczowej na jasno żółtą. Reakcje prowadzi się jeszcze 1,5 h, po czym stwierdza się przereagowanie substratu za pomocą analizy chromatografii cienkowarstwowej, stosując jako układ eluujący mieszaninę heksan:aceton w stosunku 2:1. Powstały bromoform oddziela się w rozdzielaczu poprzez ekstrakcję z eterem dietylowym. Do wodnej warstwy dodaje się następnie 0,55 g (2,89 mmola) pirosiarczynu sodu rozpuszczonego w 3 ml wody destylowanej, w celu usunięcia nadmiaru podbrominu sodu, po czym zakwasza się ją 10% wodnym roztworem H2SO4, a następnie przeprowadza się ekstrakcję z eterem dietylowym. Połączone warstwy eterowe suszy się nad bezwodnym siarczanem magnezu, a po odparowaniu rozpuszczalnika na wyparce obrotowej, otrzymuje się 0,95 g (3,26 mmola) surowego aminokwasu z N-Cbz zablokowaną grupą aminową. Surowy produkt oczyszcza się metodą chromatografii kolumnowej na silikażelu z użyciem mieszaniny eluującej heksan : aceton, użytej w proporcji 5:12.20 g of NaOH and 11.00 ml of distilled water are added to a 150 ml round bottom three-necked flask. The flask is equipped with a magnetic stirrer and a thermometer, and the flask is placed in an ice-water bath to cool the mixture to 0 ° C. While stirring vigorously, 2.64 g (16.50 mmol, 0.85 cm 3 ) of bromine are added dropwise at such a rate that the temperature of the mixture does not rise above 5 ° C. After cooling the mixture to 0 ° C., 1.60 g (5.50 mmol) of 90% pure dimethylcyclopropane ketocarbamate are added dropwise. The rest of the reaction is carried out at room temperature, and two hours after the addition of the starting material, the color of the mixture changes from orange to light yellow. The reaction is continued for 1.5 h, then the substrate is found to be converted by thin layer chromatography analysis using a 2: 1 mixture of hexane: acetone as the eluent. The resulting bromoform is separated in a separating funnel by extraction with diethyl ether. 0.55 g (2.89 mmol) of sodium metabisulfite dissolved in 3 ml of distilled water is then added to the aqueous layer to remove excess sodium hypobromite, then acidified with 10% aqueous H2SO4 followed by extraction with ether diethyl. The combined ether layers were dried over anhydrous magnesium sulfate, and after evaporation of the solvent on a rotary evaporator, 0.95 g (3.26 mmol) of crude amino acid was obtained with an amino-blocked N-Cbz group. The crude product is purified by column chromatography on silica gel using a 5: 1 hexane: acetone eluting mixture.
Produkt otrzymany według przykładu posiada następujące właściwości fizyczne i spektralne:The product obtained according to the example has the following physical and spectral properties:
PL 211 582 B1PL 211 582 B1
[a]D24 = + 15.9° (0.5, CHCI3); nD25= 1.4695; Mw= 291.20 g/mol;[α] D 24 = + 15.9 ° (0.5, CHCl 3); nD 25 = 1.4695; Mw = 291.20 g / mol;
IR (film, cm-1): 3334 (m), 3034 (ms), 2952 (s), 1714 (vs), 1531 (m), 1456 (s), 1250 (vs), 1131 (vs), 698 (s);IR (film, cm -1 ): 3334 (m), 3034 (ms), 2952 (s), 1714 (vs), 1531 (m), 1456 (s), 1250 (vs), 1131 (vs), 698 (s);
1H NMR (CDCI3, δ, ppm): 0.70-0.86 (m, 2H przy C-3 i C-5); 0.92 i 1.01; (2s, 6H przy C-7 i C-8); 2.20 (dd, J= 16.6, 8.3 Hz, 1H przy C-2); 2.39 (dd, J = 16.2, 4.6 Hz, 1H przy C-6); 2.98 (dd, 7 = 18.3, 8.9 Hz, 1H przy C-2); 3.30 (dd, J= 12.4, 6.4 Hz, 1H przy C-6), 5.03 (s, 1H przy n); 5.07 (s, 2H przy C-10); 7.23-7.27 (m, 5H przy C-12, C-13, C-14, C-15, C-16); 1 H NMR (CDCl3, δ, ppm): 0.70-0.86 (m, 2 H at C-3 and C-5); 0.92 and 1.01; (2s, 6H at C-7 and C-8); 2.20 (dd, J = 16.6, 8.3 Hz, 1H at C-2); 2.39 (dd, J = 16.2, 4.6 Hz, 1H at C-6); 2.98 (dd, J = 18.3, 8.9 Hz, 1H at C-2); 3.30 (dd, J = 12.4, 6.4 Hz, 1H at C-6), 5.03 (s, 1H at n); 5.07 (s, 2H at C-10); 7.23-7.27 (m, 5H at C-12, C-13, C-14, C-15, C-16);
13C NMR (CDCI3, δ, ppm): 14.85 (C-7), 17.74 (C-4), 22.20 (C-3), 25.72 (C-5), 28.56 (C-7), 29.64 (C-2), 37.79 (C-10), 66.71 (C-6), 128.09 i 128.54 (C-12, C-13, C-14, C-15, C-16), 136.62 (C-11), 156.45 (C-1), 179.08 (C-9). 13 C NMR (CDCl3, δ, ppm): 14.85 (C-7), 17.74 (C-4), 22.20 (C-3), 25.72 (C-5), 28.56 (C-7), 29.64 (C- 2), 37.79 (C-10), 66.71 (C-6), 128.09 and 128.54 (C-12, C-13, C-14, C-15, C-16), 136.62 (C-11), 156.45 (C-1), 179.08 (C-9).
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL389321A PL211582B1 (en) | 2009-10-20 | 2009-10-20 | Chiral N-Cbz blocked dimethylcyclopropane amino acid and process for the preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL389321A PL211582B1 (en) | 2009-10-20 | 2009-10-20 | Chiral N-Cbz blocked dimethylcyclopropane amino acid and process for the preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
PL389321A1 PL389321A1 (en) | 2011-04-26 |
PL211582B1 true PL211582B1 (en) | 2012-06-29 |
Family
ID=44060578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL389321A PL211582B1 (en) | 2009-10-20 | 2009-10-20 | Chiral N-Cbz blocked dimethylcyclopropane amino acid and process for the preparation thereof |
Country Status (1)
Country | Link |
---|---|
PL (1) | PL211582B1 (en) |
-
2009
- 2009-10-20 PL PL389321A patent/PL211582B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL389321A1 (en) | 2011-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zafrani et al. | Diethyl bromodifluoromethylphosphonate: a highly efficient and environmentally benign difluorocarbene precursor | |
KR101674806B1 (en) | Novel aminoalkylbenzothiazepine derivatives and use thereof | |
JP6980648B2 (en) | Production of 3-hydroxy-3,6-dimethylhexahydrobenzofuran-2-one and its derivatives | |
KR101816336B1 (en) | Method for producing bicyclic compound via iminium salt | |
JP5646706B2 (en) | Method for producing C-glycoside derivative | |
ITMI20120114A1 (en) | NEW PROCEDURE FOR THE PREPARATION OF 2,4,5-TRIFLUOROFENYLACETIC ACID | |
CN103402973B (en) | Compound and production method thereof, and for the production of the method for Ro 64-0796/002 | |
EP2963007B1 (en) | Synthesis of Calebin-A and its biologically active analogs | |
JP2010533644A (en) | Synthesis method of half ester | |
PL211582B1 (en) | Chiral N-Cbz blocked dimethylcyclopropane amino acid and process for the preparation thereof | |
JP2010229097A (en) | New oxazolidine derivative, new oxazolidine derivative salt and method for producing optically active compound using the oxazolidine derivative salt as asymmetric organic molecular catalyst | |
CA2835459A1 (en) | New process for synthesizing 3-(2-bromo-4,5-dimethoxyphenyl) propanenitrile, and application in the synthesis of ivabradine and its addition salts to a pharmaceutically acceptableacid. | |
TW201446712A (en) | Process for the synthesis of 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
EP3450421B1 (en) | Method for preparing treprostinil and intermediate therefor | |
JPWO2013038931A1 (en) | Process for producing 2-oxo-2H-cyclohepta [b] furan analog | |
WO2015177179A1 (en) | Improved process for preparing substituted crotonic acids | |
JP4958513B2 (en) | Method for producing sedanenolide | |
JP6345499B2 (en) | Process for the preparation of (2-hydroxy-3-oxo-cyclopent-1-enyl) -acetate | |
PL214505B1 (en) | Chiral N-Cbz blocked gem-dimethylcyclopropane gamma-amino acid and process for the preparation thereof | |
JP3918468B2 (en) | 3,3-bis (alkoxycarbonyl-methylthio) propionitrile and process for producing the same | |
JP2015529653A (en) | Process for the preparation of spiro [2.5] octane-5,7-dione | |
PL232738B1 (en) | N-[(1R,6S)-4,7,7-trimethylbicyclo[4.1.0]hept-4-en-3-yl]acetamide and method for obtaining it | |
PL213059B1 (en) | Chiral dimethylcyclopropane carboxyester and process for the preparation thereof | |
JPS5822031B2 (en) | β-Ketosulfoxides and their production method | |
JP2019142803A (en) | Production method of primary amine compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
LAPS | Decisions on the lapse of the protection rights |
Effective date: 20121020 |